A phase 1 first-in-human study of XMT-1107, a polymer-conjugated fumagillol derivative, in patients (pts) with advanced solid tumors.
Johanna C. Bendell
Research Funding - Mersana Therapeutics
Geoffrey Shapiro
Research Funding - Mersana Therapeutics
Edward A. Sausville
Research Funding - Mersana Therapeutics
Suzanne Fields Jones
Research Funding - Mersana Therapeutics
John Frederick Hilton
Research Funding - Mersana Therapeutics
Dana Shkolny
Consultant or Advisory Role - Mersana Therapeutics
Stock Ownership - Mersana Therapeutics
Burkhard Blank
Consultant or Advisory Role - Mersana Therapeutics
Stock Ownership - Mersana Therapeutics
Donald Alan Bergstrom
Employment or Leadership Position - Mersana Therapeutics
Stock Ownership - Mersana Therapeutics